Subscribe to our newsletter

Investor Resources

Who We Are

Liminal BioSciences is a development-stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using our drug discovery platform with a data-driven approach. Liminal BioSciences has its registered office in Bellevlle, Ontario and talent hubs in Laval, Quebec, Canada, and Cambridge, UK.

Our common shares are listed for trading on the Nasdaq Market (LMNL).

Stock Quote
NASDAQLMNL
OUR DEVELOPMENT PROGRAMS

GPR84 Antagonist

The GPR84 receptor is primarily expressed in immune cells in addition to multiple organ systems. It plays a key role in the linkage and regulation of the inflammatory and metabolic response, and promotes fibrosis. Learn more.

OXER1 Antagonist 

OXER1 is a GPCR receptor which is mainly expressed ininflammatory cells. OXER1 is highly selective for 5 oxo ETE, one of the most powerful chemo attractants and activators of eosinophils. Learn more.

Recent News
Mar 15, 2023
Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results

CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery program aiming for the development of...

Mar 13, 2023
Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its fourth quarter and year ended 2022 financial results after market close on

Feb 15, 2023
Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price Requirement

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it has received written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has...

More News

Corporate Presentation

Latest Events
Q4 and Year End 2022 Financial Results Conference Call
Thursday, March 16, 2023
8:30am - 9:30am EDT

Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday March 16, 2023. To join the conference call without operator assistance, you may register...

Q3 2022 Results Conference Call
Thursday, November 10, 2022
8:30am - 9:30am EST

Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday November 10, 2022. The telephone numbers to access the conference call are 888-205-6786 and...

H.C. Wainwright 24th Annual Global Investment Conference - September 12-14, 2022
Wednesday, September 14, 2022
9:30am EDT
Investor Resources

Find out more on how Liminal BioSciences (NASDAQ: LMNL) is developing a pipeline of novel small molecule therapeutics.